For diseases of the eye, biopsy is not possible, so there is a reliance on imaging technology, which poses a significant challenge of drug development, and requires the incorporation of imaging biomarkers (IB). 

Dry AMD is a complex disease of innate immunity, oxidative stress and lipid dysregulation that relies on IBs. Unfortunately, the only measure as a clinical trial endpoint is the standard Fundus Autofluorescence (FAF) which can only measure tissue after it is lost, limiting prevention studies.